Sloand 2004.

Methods	randomized, placebo-controlled trial
Participants	25 adult men and women with ESRD (on either hemodialysis or peritoneal dialysis) who also had RLS by IRLSSG criteria, recruited from the dialysis units of a single medical center (USA)
Interventions	Active: IV iron dextran given as: 30 mg test dose over 3 min, followed by 970 mg (in 485 mL volume) over 3 hrs if no reaction to the test dose Placebo: NaCl given in the same volume & and with the same timing as the intervention group
Outcomes	ferritin, Hct, GI side effects, U of R severity score (10 pt scale where 0=none, 10=bad) at 0, 1, 2, 4 wks
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	method of randomization not specified
Allocation concealment (selection bias)	Low risk
Blinding (performance bias and detection bias) All outcomes	Low risk
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	two placebo patients dropped out after infusion, but Figure 1 reports data on all 14 placebo patients
Selective reporting (reporting bias)	Unclear risk	no study protocol available
Other bias	Unclear risk	baseline imbalance of 2 points in RLS severity score; there was also a broader range of scores in the treated group; imbalance in duration of dialysis